Neurodegenerative Disorders Area, Biodonostia Health Research Institute, San Sebastián, Spain.
Biomedical Research Networking Centre Consortium for the area of Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
Mov Disord. 2018 Nov;33(11):1809-1813. doi: 10.1002/mds.27518. Epub 2018 Nov 13.
There is a need for biomarkers of dementia in PD.
To determine if the levels of the main CSF proteins and their ratios are associated with deterioration in cognition and progression to dementia in the short to mid term.
The Parkinson's Progression Markers Initiative database was used as an exploratory cohort, and a center-based cohort was used as a replication cohort. Amyloid ß1-42, total tau, threonine-181 phosphorylated tau, and α-synuclein in the CSF and the ratios of these proteins were assessed.
In the Parkinson's Progression Markers Initiative cohort (n = 281), the total tau/amyloid ß1-42, total tau/α-synuclein, total tau/amyloid ß1-42+α-synuclein, and amyloid ß1-42/total tau ratios were associated with a risk of progression to dementia over a 3-year follow-up. In the replication cohort (n = 40), the total tau/α-synuclein and total tau/amyloid ß1-42+α-synuclein ratios were associated with progression to dementia over a 41-month follow-up.
Ratios of the main proteins found in PD patient brain inclusions that can be measured in the CSF appear to have value as short- to mid-term predictors of dementia. © 2018 International Parkinson and Movement Disorder Society.
在 PD 中需要有痴呆的生物标志物。
确定 CSF 中主要蛋白质及其比值的水平是否与认知恶化和短期至中期进展为痴呆相关。
使用帕金森病进展标志物倡议数据库作为探索性队列,以及以中心为基础的队列作为复制队列。CSF 中的淀粉样蛋白 β1-42、总 tau、苏氨酸 181 磷酸化 tau 和 α-突触核蛋白及其比值进行评估。
在帕金森病进展标志物倡议队列(n=281)中,总 tau/淀粉样蛋白 β1-42、总 tau/α-突触核蛋白、总 tau/淀粉样蛋白 β1-42+α-突触核蛋白和淀粉样蛋白 β1-42/总 tau 比值与 3 年随访期间进展为痴呆的风险相关。在复制队列(n=40)中,总 tau/α-突触核蛋白和总 tau/淀粉样蛋白 β1-42+α-突触核蛋白比值与 41 个月随访期间进展为痴呆相关。
可在 CSF 中测量的 PD 患者脑内含物中主要蛋白质的比值似乎可作为短期至中期痴呆的预测指标。© 2018 国际帕金森病和运动障碍学会。